Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dmitry Litvinov

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal for Immunotherapy of Cancer|June 6, 2024
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALLEkaterina Mikhailova, Alexander Popov, Julia Roumiantseva, et al.
Cancers|December 9, 2023
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALLAlexander Popov, Günter Henze, Julia Roumiantseva, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 studyAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Pediatric Blood & Cancer|March 28, 2023
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurementAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Cancer Medicine|April 23, 2024
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocolAlexander Popov, Guenter Henze, Grigory Tsaur, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2019
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002Alexander Karachunskiy, Gesche Tallen, Julia Roumiantseva, et al.
Blood Advances|April 21, 2022
Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemiaOlga Goronkova, Galina Novichkova, Tatiana Salimova, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal for Immunotherapy of Cancer|June 6, 2024
Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALLEkaterina Mikhailova, Alexander Popov, Julia Roumiantseva, et al.
Cancers|December 9, 2023
A Single Dose of PEG-Asparaginase at the Beginning of Induction Not Only Accelerates MRD Clearance but Also Improves Long-Term Outcome in Children with B-Lineage ALLAlexander Popov, Günter Henze, Julia Roumiantseva, et al.
Journal of Cancer Research and Clinical Oncology|September 28, 2022
One-point flow cytometric MRD measurement to identify children with excellent outcome after intermediate-risk BCP-ALL: results of the ALL-MB 2008 studyAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Pediatric Blood & Cancer|March 28, 2023
A simple procedure to identify children with B-lineage acute lymphoblastic leukemia who can be successfully treated with low or moderate intensity: Sequential versus single-point minimal residual disease measurementAlexander Popov, Guenter Henze, Julia Roumiantseva, et al.
Cancer Medicine|April 23, 2024
Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non-high-risk acute lymphoblastic leukemia treated according to the ALL-MB 2008 protocolAlexander Popov, Guenter Henze, Grigory Tsaur, et al.
Journal of Cancer Research and Clinical Oncology|March 7, 2019
Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002Alexander Karachunskiy, Gesche Tallen, Julia Roumiantseva, et al.
Blood Advances|April 21, 2022
Efficacy of combined immunosuppression with or without eltrombopag in children with newly diagnosed aplastic anemiaOlga Goronkova, Galina Novichkova, Tatiana Salimova, et al.
Pageof 3